The coronavirus pandemic has powered biotech stocks in 2020.
But how do we actually forecast profits, what’s been driving the recent volatility of biotech stocks, and what can you expect from the group going forward?
Let’s dive in.
Valuing a biotech company means zeroing in on the value each drug can bring the company and then summing up the value of all of those drugs.
But figuring out the value of a single drug is complicated, and depends on hard-to-find answers to a number of questions.
How many people might need the drug in each year of the valuation? How much market share can each drug maker take? What can we reasonably expect the price per dose to be? Answers to these give us revenue attributable to the drug over the years the drug is in use.
Then, what are the costs attributable to each drug? How much money in operating expenses is needed? What about capital expenditures? So how much free cash flow is attributable to each drug?
Next, you need to discount the free cash flow by the likelihood the drug is approved because we don’t know the drug will really be approved. For example. in phase one there may be a 10% probability of success. So we would reduce the free cash flow value by 90%. As the drug moves closer to approval, we will have a much lower discount rate. And then, of course, we have to discount the company’s cost of capital.
Then, we add up the value of discounted cash flow of all drugs the company is planning on making and selling.
To see what the outlook is and the risk-reward scenario for these stocks, watch the quick video above.
More 2021 Best Stocks' Videos:
- Dividend Stocks to Watch in 2021
- 5 Industrial Stocks to Watch in 2021
- Expedia and JetBlue Are Among Some of the Best Travel Stocks for 2021
- #BestEnergyStocks to Watch In 2021
- #BestGamingStocks to Watch In 2021
- Three Stocks Under $10 for 2021
- The Best Retail Stocks for 2021 Are Names That Might Surprise You